RecruitingAdvanced Solid TumorMetastatic Solid Tumor
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Sponsor: Daiichi Sankyo
You may qualify if…
- ✓ Sign and date the main Informed Consent Form (ICF).
- ✓ Has a left ventricular ejection fraction ≥50% by either an echocardiogram or multigated acquisition within 28 days of enrollment.
- ✓ Has adequate organ function.
- ✓ Measurable disease based on RECIST V1.1.
- ✓ Eastern Cooperative Oncology Group performance status score of 0 or 1.
- ✓ Additional inclusion criteria for Part 1
- ✓ Has a histologically or cytologically documented locally advanced, metastatic, or unresectable solid malignant tumors.
- ✓ Additional inclusion criteria for Part 2
You may not qualify if…
- ✕ Has had prior treatment targeting mucin 1 (MUC1) or TA-MUC1.
- ✕ Has spinal cord compression or clinically active central nervous system metastases.
- ✕ Has multiple primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years.
- ✕ Has any history of ILD/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening. Participants may be eligible if they had history of radiation pneumonitis that did not require steroids.
- ✕ Has active or uncontrolled human immunodeficiency virus (HIV) infection.
- ✕ Has evidence of active or uncontrolled hepatitis B virus or hepatitis C virus infection.
- ✕ Any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.
- ✕ Has an active (ie, symptomatic and/or on-treatment), known, or suspected autoimmune disease.
Where it's recruiting
Source: ClinicalTrials.gov · NCT05875168 · last updated 2026-07-17